Other formats:
BibTeX
LaTeX
RIS
@article{1703256,
author = {Halámková, Jana and Kazda, Tomáš and AdamkovaandKrakorova, Dagmar and Rybníčková, Sylva and Kiss, Igor and Demlová, Regina},
article_location = {Philadelphia},
article_number = {42},
doi = {http://dx.doi.org/10.1097/MD.0000000000022634},
keywords = {abdominal lymphedema; case report; everolimus-related adverse event; mammalian target of rapamycin inhibitors; renal cancer; unilateral lymphedema},
language = {eng},
issn = {0025-7974},
journal = {Medicine},
title = {Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report},
url = {https://journals.lww.com/md-journal/Fulltext/2020/10160/Everolimus_related_unilateral_abdominal_lymphedema.33.aspx},
volume = {99},
year = {2020}
}
TY - JOUR
ID - 1703256
AU - Halámková, Jana - Kazda, Tomáš - Adamkova-Krakorova, Dagmar - Rybníčková, Sylva - Kiss, Igor - Demlová, Regina
PY - 2020
TI - Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report
JF - Medicine
VL - 99
IS - 42
SP - 1-4
EP - 1-4
PB - Lippincott Williams & Wilkins
SN - 00257974
KW - abdominal lymphedema
KW - case report
KW - everolimus-related adverse event
KW - mammalian target of rapamycin inhibitors
KW - renal cancer
KW - unilateral lymphedema
UR - https://journals.lww.com/md-journal/Fulltext/2020/10160/Everolimus_related_unilateral_abdominal_lymphedema.33.aspx
L2 - https://journals.lww.com/md-journal/Fulltext/2020/10160/Everolimus_related_unilateral_abdominal_lymphedema.33.aspx
N2 - Rationale: Unilateral manifestation of lymphedema during everolimus therapy has been described only rarely, mostly in transplant recipients. Patient concerns: We report the first case of a patient who developed unilateral abdominal lymphedema, during a short period of everolimus treatment for renal cancer. Diagnosis: The abdominal asymmetry occurred only on the right side of the abdomen, neither ultrasound nor CT scan detected ascites but showed enlargement of the abdominal wall. The Naranjo Adverse Drug Reaction Probability scale was evaluated, in this case, a score of 6 indicated a probable adverse reaction to everolimus. Interventions: Discontinuation of everolimus therapy led to immediate alleviation and reduction of the lymphedema, with worsening once again after initiating retreatment with everolimus at a reduced dose. Outcomes: The patient's lymphedema recovered after discontinuation of everolimus. Lessons: This rare case demonstrates the importance of the selection of mammalian target of rapamycin inhibitors using caution, especially for patients with a high risk of developing lymphedema.
ER -
HALÁMKOVÁ, Jana, Tomáš KAZDA, Dagmar ADAMKOVA-KRAKOROVA, Sylva RYBNÍČKOVÁ, Igor KISS and Regina DEMLOVÁ. Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report. \textit{Medicine}. Philadelphia: Lippincott Williams \&{} Wilkins, 2020, vol.~99, No~42, p.~1-4. ISSN~0025-7974. Available from: https://dx.doi.org/10.1097/MD.0000000000022634.
|
